Clinuvel Pharmaceuticals Ltd (Clinuvel) is a biopharmaceutical company that specializes in the development and commercialization of melanocortin-based therapies and skin-health products. The company focuses on developing treatments for serious skin and brain conditions, including EPP, vitiligo, variegate porphyria, xeroderma pigmentosum, arterial ischemic stroke, and Parkinson’s disease.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Clinuvel advanced R&D through its Singapore Vallaurix Pte Ltd and expanded the Vallaurix RD&I Centre, which supports analytical, biological, formulation, and peptide-science work, including OTC products, Prenumbra liquid afamelanotide, and second-generation melanocortins such as CUV9900, phimelanotide, and parvysmelanotide. The pipeline included Scenesse for adult EPP, already commercial in multiple markets; adolescent EPP, with CUV052 data submitted to the EMA; Phase III vitiligo programs CUV105, which completed treatment and follow-up, and CUV107, which remained in design; Neuracthel Instant, with validated GMP manufacturing and first European filing expected in H2 2026; and the VLRX-L controlled-release liquid peptide platform, which entered preclinical dosing in January 2026. Clinuvel also stated that it continued strengthening patent and trademark protection across multiple jurisdictions. In FY2026, the company invested AUD18.1 million in its R&D activities, which is 19.3% of revenue.